Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.

Malik M, Nitiss KC, Enriquez-Rios V, Nitiss JL.

Mol Cancer Ther. 2006 Jun;5(6):1405-14.

2.

Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage.

Nitiss KC, Malik M, He X, White SW, Nitiss JL.

Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):8953-8. Epub 2006 Jun 2.

3.

Genetic evidence for involvement of two distinct nonhomologous end-joining pathways in repair of topoisomerase II-mediated DNA damage.

Adachi N, Iiizumi S, So S, Koyama H.

Biochem Biophys Res Commun. 2004 Jun 11;318(4):856-61.

PMID:
15147950
4.

Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks.

Rogojina AT, Nitiss JL.

J Biol Chem. 2008 Oct 24;283(43):29239-50. doi: 10.1074/jbc.M804058200. Epub 2008 Aug 22.

5.

Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks.

Sabourin M, Nitiss JL, Nitiss KC, Tatebayashi K, Ikeda H, Osheroff N.

Nucleic Acids Res. 2003 Aug 1;31(15):4373-84.

6.
7.

Evidence for a role of vertebrate Rad52 in the repair of topoisomerase II-mediated DNA damage.

Adachi N, Iiizumi S, Koyama H.

DNA Cell Biol. 2005 Jun;24(6):388-93.

PMID:
15941391
8.

Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II.

Nitiss JL, Liu YX, Harbury P, Jannatipour M, Wasserman R, Wang JC.

Cancer Res. 1992 Aug 15;52(16):4467-72.

9.
10.

Topoisomerase II-mediated DNA damage is differently repaired during the cell cycle by non-homologous end joining and homologous recombination.

de Campos-Nebel M, Larripa I, González-Cid M.

PLoS One. 2010 Sep 2;5(9). pii: e12541. doi: 10.1371/journal.pone.0012541.

11.

Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.

Maede Y, Shimizu H, Fukushima T, Kogame T, Nakamura T, Miki T, Takeda S, Pommier Y, Murai J.

Mol Cancer Ther. 2014 Jan;13(1):214-20. doi: 10.1158/1535-7163.MCT-13-0551. Epub 2013 Oct 15.

12.
13.

Mms22p protects Saccharomyces cerevisiae from DNA damage induced by topoisomerase II.

Baldwin EL, Berger AC, Corbett AH, Osheroff N.

Nucleic Acids Res. 2005 Feb 17;33(3):1021-30. Print 2005.

15.

The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.

Jannatipour M, Liu YX, Nitiss JL.

J Biol Chem. 1993 Sep 5;268(25):18586-92.

17.

DNA topoisomerase-targeting antitumor drugs can be studied in yeast.

Nitiss J, Wang JC.

Proc Natl Acad Sci U S A. 1988 Oct;85(20):7501-5.

19.

NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.

Toyoda E, Kagaya S, Cowell IG, Kurosawa A, Kamoshita K, Nishikawa K, Iiizumi S, Koyama H, Austin CA, Adachi N.

J Biol Chem. 2008 Aug 29;283(35):23711-20. doi: 10.1074/jbc.M803936200. Epub 2008 Jul 2.

20.

DNA double-strand break repair pathways and cellular tolerance to inhibitors of topoisomerase II.

Caldecott K, Banks G, Jeggo P.

Cancer Res. 1990 Sep 15;50(18):5778-83.

Supplemental Content

Support Center